In vivo electropharmacological effects of amiodarone and candesartan on atria of chronic atrioventricular block dogs

Journal of Pharmacological Sciences

Volumn 103, Issue 2, 2007, Pages 207-213

  Wang, Kai ^a   Takahara, Akira ^a   Nakamura, Yuji ^a   Aonuma, Kazutaka ^b   Matsumoto, Masahiko ^a   Sugiyama, Atsushi ^a,c  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Yamanashi Research Center of Clinical Pharmacology   (Japan)

Author keywords

Amiodarone; Atrial fibrillation; Atrioventricular block; Candesartan

Indexed keywords

AMIODARONE; ANCARON; ANGIOTENSIN II; CANDESARTAN HEXETIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR BLOCK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART ATRIUM; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART MUSCLE REFRACTORY PERIOD; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; TORSADE DES POINTES;

EID: 33847154002     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0060945     Document Type: Article

References (20)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation. 1998;98:946-952.
2. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res. 2002;54:347-360.
3. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation. 2003;107:1440-1446.
4. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:2197-2204.
5. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999; 100: 87-95.
6. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y, et al. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn J Pharmacol. 2002;88:341-350.
7. Vos MA, de Groot SHM, Verduyn SC, van der Zande J, Leunissen HDM, Cleutjens JPM, et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation. 1998;98:1125-1135.
8. Volders PGA, Sipido KR, Vos MA, Kulcsar A, Verduyn SC, Wellens HJJ. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation. 1998;98:1136-1147.
9. Baim DS, Grossman W. Percutaneous approach including trans-septal and apical puncture. In: Baim DS, editor. Cardiac catheterization, angiography, and intervention. 5th ed. Baltimore: Williams & Wilkins; 1995. p. 57-81.
10. Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K. Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for Torsades. Toxicol Appl Pharmacol. 2000;169:8-16.
11. Sugiyama A, Satoh Y, Hashimoto K. Acute electropharmacological effects of intravenously administered amiodarone assessed in the in vivo canine model. Jpn J Pharmacol. 2001;87:74-82.
12. Harris L, Roncucci R, editors. Amiodarone. Paris: Médecine et Sciences Internationales; 1986.
13. Ito K, Shiomi M, Kito G. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res. 1995;8:69-75.
14. Onishi K, Dohi K, Koji T, Funabiki K, Kitamura T, Imanaka-Yoshida K, et al. Candesartan prevents myocardial fibrosis during progression of congestive heart failure. J Cardiovasc Pharmacol. 2004;43:860-867.
15. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol. 1999;84:20R-28R.
16. + current. Circulation. 2001;103:1317-1324.
17. Cohen CJ, Spires S, Van Skiver D. Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992;100:703-728.
18. Ashikaga K, Kobayashi T, Kimura M, Owada S, Sasaki S, Iwasa A, et al. Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. Eur J Pharmacol. 2003;536:148-153.
19. Wang K, Sugiyama A, Takahara A, Satoh Y, Honsho S, Nakamura Y, et al. Anti-atrial fibrillatory effects of acute and chronic administration of amiodarone. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi). 2005;125:14P. (in Japanese)
20. Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol. 2000;83:1-19.